Single oral doses of MK-0812 increased plasma CCL2 in wild-type C57BL/6 mice at four hours. This pharmacodynamic response should be distinguished from disease improvement. [1]
In NSG mice bearing MDA-MB-231 xenografts, oral MK-0812 given with a three-week docetaxel course reduced subsequent tumor regrowth and the tumor ALDEFLUOR-bright fraction compared with docetaxel plus vehicle. The result is specific to the combination design. [2]
Oral MK-0812 increases plasma CCL2 in mice
Animal study · Female C57BL/6 mice, 4–6 weeks old; n = 5 per group in Methods [1]
At four hours after oral MK-0812, plasma CCL2 increased in the dose-ranging experiment. Drug exposure was assessed in the same plasma samples. This is a pharmacodynamic result, not a disease-efficacy test.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Single dose
- Treatment course
- 4 h to the adopted plasma endpoint
- Vehicle
- 1% HPMC
- MK-0812 dose range
- Model: Female wild-type C57BL/6 mice
- Reported limits: No disease-severity endpoint is part of this experiment; Figure 1A error-bar definition is not given.
Methods and source locations
Compound reported in the paper: MK-0812; Compound label in the paper: MK-0812
Evidence concerns the named literature compound. It does not validate an Adooq lot, establish analytical stereochemical equivalence, or demonstrate a particular salt form. Reported doses are retained without salt conversion.
Figure 1A-B and caption; first Results paragraph; Methods: In Vivo Studies; Reagents
Plasma CCL2 four hours after dosing: CCL2 ELISA; Figure 1A viewed. The approximate plateau is explicitly reported in Results, not inferred as an exact value from the graph. — Figure 1A-B and caption; first Results paragraph; Methods: In Vivo Studies; Reagents
MK-0812 dose range · Figure 1A-B and caption; first Results paragraph; Methods: In Vivo Studies; Reagents
MK-0812 co-treatment limits post-docetaxel xenograft regrowth
Animal study · Female NSG mice bearing orthotopic MDA-MB-231-shCTRL xenografts; n = 8 for tumor-volume data (Figure 4B) [2]
Adding oral MK-0812 during the docetaxel course reduced subsequent tumor regrowth and the ALDEFLUOR-bright fraction relative to docetaxel plus vehicle. The design does not establish MK-0812 monotherapy efficacy.
- Docetaxel plus MK-0812
- Model: NSG mice with MDA-MB-231-shCTRL tumors
- Route: MK-0812 oral; docetaxel route not separately specified for Figure 4A-C
- Frequency: MK-0812 twice daily; docetaxel weekly for 3 weeks
- Treatment course: MK-0812 30 days from chemotherapy initiation
- Vehicle: Not specified
- Reported limits: Vehicle composition and the docetaxel dose specifically assigned to Figure 4A-C are not restated. Figure 4B reports n = 8; Figure 4C does not separately specify n. The schematic and prose differ on the approximate starting tumor size, which is not used in this record.
- Docetaxel plus vehicle
- Model: NSG mice with MDA-MB-231-shCTRL tumors
- Route: Vehicle and docetaxel routes not separately specified for Figure 4A-C
- Frequency: Docetaxel weekly for 3 weeks; vehicle schedule not separately stated
- Treatment course: Docetaxel on days 24, 31 and 38; comparator followed for regrowth
- Vehicle: Composition not specified
- Reported limits: Vehicle composition and the docetaxel dose specifically assigned to Figure 4A-C are not restated. Figure 4B reports n = 8; Figure 4C does not separately specify n. The schematic and prose differ on the approximate starting tumor size, which is not used in this record.
Methods and source locations
Compound reported in the paper: MK-0812; Compound label in the paper: CCR2 inhibitor / CCR2i (MK-0812)
Evidence concerns the named literature compound. It does not validate an Adooq lot, establish analytical stereochemical equivalence, or demonstrate a particular salt form. Reported doses are retained without salt conversion.
Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics
Post-chemotherapy tumor regrowth: Caliper tumor-volume measurements; Figure 4B. n = 8; shared Statistics states mean ± SD. — Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics
ALDEFLUOR-bright fraction in dissociated tumors: ALDEFLUOR flow cytometry; Figure 4C. Panel-specific replicate number is not separately specified. — Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics
Docetaxel plus MK-0812 · Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics
Docetaxel plus vehicle · Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics